Research & Reviews: Journal of Pharmacology and Toxicological Studies
e-ISSN: 2322-0139
p-ISSN: 2322-0120

Cellular Mechanisms of Targeted Therapy in Cancer Treatment

Diana Heller*

Department of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden

Perspective

Received: 29-Nov-2024, Manuscript No. JPTS-24-156459; **Editor assigned:** 02-Dec-2024, PreQC No. JPTS-24-156459 (PQ); **Reviewed:** 16-Dec-2024, QC No. JPTS-24-156459; **Revised:** 23-Dec-2024, Manuscript No. JPTS-24-156459 (R); **Published:** 30-Dec-2024, DOI:10.4172/2322-0139.12.4.001

***For Correspondence:**
Diana Heller, Department of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden
E-mail: Dianaheller@hotmail.com

Citation: Heller D. Cellular Mechanisms of Targeted Therapy in Cancer Treatment. J Pharmacol Toxicol Stud.2024;12:010.

DESCRIPTION

Cancer is a complex and heterogeneous group of diseases characterized by uncontrolled cell growth and spread to other parts of the body. Traditionally, cancer treatment has relied on surgery, chemotherapy, and radiation, all of which are aimed at killing cancer cells or reducing tumour size. While these therapies can be effective, they often come with significant side effects due to their lack of specificity. Over the past few decades, targeted therapy has emerged as a promising approach to cancer treatment, offering greater specificity and reduced toxicity. This article explores the cellular mechanisms of targeted therapy in cancer treatment, highlighting how targeted therapies work, the molecular targets they aim for, and the challenges that remain in their development.

Targeted therapy refers to a type of cancer treatment that specifically targets molecular mechanisms involved in the growth and spread of cancer cells. Unlike traditional chemotherapy, which indiscriminately kills rapidly dividing cells, targeted therapies are designed to interact with specific molecules or pathways that are involved in tumour development. These therapies can target specific proteins, receptors, or genetic mutations that are unique to cancer cells, allowing for more precise treatment with fewer side effects.

e-ISSN: 2322-0139
p-ISSN: 2322-0120

Hydroxyapatite and silica nanoparticles are used in bone regeneration and tissue engineering due to their biocompatibility and ability to support cellular growth.

Targeted therapy can be classified into two main types: small molecules and monoclonal antibodies. Small molecules are typically administered orally and work inside the cell to inhibit specific signaling pathways or proteins. Monoclonal antibodies, on the other hand, are usually administered intravenously and act on the surface of cancer cells by binding to specific receptors or antigens.

One of the most common mechanisms targeted by cancer therapies is the disruption of abnormal signal transduction pathways that drive cancer cell growth and survival. These signaling pathways regulate important cellular processes such as cell proliferation, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels to supply the tumor).

HER2 is another receptor that is overexpressed in certain cancers, such as breast and gastric cancers. Overexpression of HER2 leads to uncontrolled cell proliferation. Trastuzumab (Herceptin), a monoclonal antibody, targets HER2 and prevents its activation, which can slow down or stop the growth of HER2-positive breast cancer cells.

While targeted therapies have shown significant promise, several challenges remain in their widespread use. One of the primary obstacles is the development of drug resistance. Cancer cells can acquire mutations that bypass the inhibition of specific targets, leading to treatment failure. For example, some patients with EGFR-mutant lung cancer develop resistance to EGFR inhibitors through secondary mutations in the EGFR gene. Combination therapies, which target multiple pathways simultaneously, are being explored to overcome this resistance.

Despite these challenges, the future of targeted cancer therapy remains promising. Advances in genomics, proteomics, and immunology continue to uncover new molecular targets and pathways that can be exploited for cancer treatment. Personalized medicine, which tailors treatment to the individual genetic profile of a patient's tumor, is also becoming a key aspect of cancer care. By continuing to refine our understanding of the cellular mechanisms involved in cancer and therapy resistance, targeted therapies are poised to play an increasingly important role in the fight against cancer.

Targeted therapy represents a transformative approach to cancer treatment, offering more specific and effective ways to treat cancer with fewer side effects than traditional therapies. By focusing on molecular pathways that are unique to cancer cells, targeted therapies can inhibit tumor growth, promote cell death, and block the tumor's ability to evade the immune system. As we gain deeper insights into the complex molecular mechanisms of cancer, the development of targeted therapies will continue to evolve, offering hope for more effective treatments for a variety of cancers.